Teverelix | CAS# 151272-78-5 | LHRH Antagonist

MedKoo Cat#: 571439 | Name: Teverelix

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Teverelix is a water-soluble synthetic peptidic luteinizing hormone-releasing hormone (LHRH) antagonist. It suppresses luteinizing hormone and testosterone, with duration of effects depending on dosage.

Chemical Structure

Teverelix

CAS#151272-78-5

Theoretical Analysis

MedKoo Cat#: 571439

Name: Teverelix

CAS#: 151272-78-5

Chemical Formula: C74H100ClN15O14

Exact Mass: 1457.7263

Molecular Weight: 1459.16

Elemental Analysis: C, 60.91; H, 6.91; Cl, 2.43; N, 14.40; O, 15.35

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Teverelix

IUPAC/Chemical Name

D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-

InChi Key

NOENHWMKHNSHGX-IAOPALDYSA-N

InChi Code

InChI=1S/C74H100ClN15O14/c1-43(2)35-57(66(96)84-56(19-10-11-32-79-44(3)4)73(103)90-34-14-20-63(90)72(102)81-45(5)64(76)94)85-65(95)55(18-9-12-33-80-74(77)104)83-68(98)59(38-48-24-29-54(93)30-25-48)88-71(101)62(42-91)89-70(100)61(40-50-15-13-31-78-41-50)87-69(99)60(37-47-22-27-53(75)28-23-47)86-67(97)58(82-46(6)92)39-49-21-26-51-16-7-8-17-52(51)36-49/h7-8,13,15-17,21-31,36,41,43-45,55-63,79,91,93H,9-12,14,18-20,32-35,37-40,42H2,1-6H3,(H2,76,94)(H,81,102)(H,82,92)(H,83,98)(H,84,96)(H,85,95)(H,86,97)(H,87,99)(H,88,101)(H,89,100)(H3,77,80,104)/t45-,55-,56+,57+,58-,59+,60-,61-,62+,63+/m1/s1

SMILES Code

C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCCNC(C)C)NC([C@H](CC(C)C)NC([C@@H](CCCCNC(N)=O)NC([C@H](CC2=CC=C(O)C=C2)NC([C@H](CO)NC([C@@H](CC3=CC=CN=C3)NC([C@@H](CC4=CC=C(Cl)C=C4)NC([C@@H](CC5=CC=C6C=CC=CC6=C5)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,459.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Erb K, Pechstein B, Schueler A, Engel J, Hermann R. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. Clin Pharmacol Ther. 2000 Jun;67(6):660-9. PubMed PMID: 10872648. 2: Schneider A, Lang A, Naumann W. Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix. J Fluoresc. 2010 Nov;20(6):1233-40. doi: 10.1007/s10895-010-0674-5. Epub 2010 Jun 1. PubMed PMID: 20514551. 3: Sorensen S, Rondeau JJ, Lenaerts V, Boutignon F, Wüthrich P, Deghenghi R, Adam A, Ong H. Radioimmunoassay of Antarelix, a luteinizing hormone releasing-hormone antagonist, in plasma and its application for pharmacokinetic study in dogs. J Immunoassay. 1996 Aug;17(3):205-26. PubMed PMID: 8842981. 4: Briant C, Ottogalli M, Morel M, Guillaume D. Use of a GnRH antagonist, antarelix, associated or not with hCG, to control ovulation in cyclic pony mares. Domest Anim Endocrinol. 2003 May;24(4):305-22. PubMed PMID: 12742549. 5: Mallardé D, Boutignon F, Moine F, Barré E, David S, Touchet H, Ferruti P, Deghenghi R. PLGA-PEG microspheres of teverelix: influence of polymer type on microsphere characteristics and on teverelix in vitro release. Int J Pharm. 2003 Aug 11;261(1-2):69-80. PubMed PMID: 12878396. 6: Briant C, Ottogalli M, Guillaume D. Attempt to control the day of ovulation in cycling pony mares by associating a GnRH antagonist with hCG. Domest Anim Endocrinol. 2004 Aug;27(2):165-78. PubMed PMID: 15219935. 7: Gonzalez-Bulnes A, Santiago-Moreno J, Garcia-Garcia RM, Souza CJ, Lopez-Sebastian A, McNeilly AS. Effect of GnRH antagonists treatment on gonadotrophin secretion, follicular development and inhibin A secretion in goats. Theriogenology. 2004 Apr 1;61(5):977-85. PubMed PMID: 14757481. 8: Gonzalez Añover P, Gonzalez-Bulnes A, Veiga-Lopez A, Garcia-Garcia RM, McNeilly AS, Encinas T. Effects of growth hormone and gonadotrophin releasing hormone antagonists on ovarian follicle growth in sheep. J Vet Pharmacol Ther. 2006 Oct;29(5):373-7. PubMed PMID: 16958781. 9: Gianotti L, Veldhuis JD, Destefanis S, Lanfranco F, Ramunni J, Arvat E, Marzetto M, Boutignon F, Deghenghi R, Ghigo E. Suppression and recovery of LH secretion by a potent and selective GnRH-receptor antagonist peptide in healthy early follicular-phase women are mediated via selective control of LH secretory burst mass. Clin Endocrinol (Oxf). 2003 Oct;59(4):526-32. PubMed PMID: 14510918. 10: Caraty A, Blomenröhr M, Vogel GM, Lomet D, Briant C, Beltramo M. RF9 powerfully stimulates gonadotrophin secretion in the ewe: evidence for a seasonal threshold of sensitivity. J Neuroendocrinol. 2012 May;24(5):725-36. doi: 10.1111/j.1365-2826.2012.02283.x. PubMed PMID: 22283564. 11: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PubMed PMID: 17805439. 12: Brüssow KP, Schneider F, Nürnberg G. Alteration of gonadotrophin and steroid hormone release, and of ovarian function by a GnRH antagonist in gilts. Anim Reprod Sci. 2001 Apr 30;66(1-2):117-28. PubMed PMID: 11343847. 13: Oussaid B, Lonergan P, Khatir H, Guler A, Monniaux D, Touze JL, Beckers JF, Cognie Y, Mermillod P. Effect of GnRH antagonist-induced prolonged follicular phase on follicular atresia and oocyte developmental competence in vitro in superovulated heifers. J Reprod Fertil. 2000 Jan;118(1):137-44. PubMed PMID: 10793635. 14: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Jan-Feb;28(1):31-63. PubMed PMID: 16541195. 15: Guillaume D, Bruneau B, Briant C. Comparison of the effects of two GnRH antagonists on LH and FSH secretion, follicular growth and ovulation in the mare. Reprod Nutr Dev. 2002 May-Jun;42(3):251-64. PubMed PMID: 12405453. 16: Hinojosa AM, Bloeser JR, Thomson SR, Watson ED. The effect of a GnRH antagonist on endocrine and seminal parameters in stallions. Theriogenology. 2001 Sep 15;56(5):903-12. PubMed PMID: 11665891. 17: Odum J, Tinwell H, Jones K, Van Miller JP, Joiner RL, Tobin G, Kawasaki H, Deghenghi R, Ashby J. Effect of rodent diets on the sexual development of the rat. Toxicol Sci. 2001 May;61(1):115-27. PubMed PMID: 11294982. 18: Schneider F, Bellmann A, Becker F, Bambang Poernomo S, Rehfeldt C, Nürnberg G, Kanitz W. Gonadotropin release in periovulatory heifers after GnRH analogs measured by two types of immunoassays. Exp Clin Endocrinol Diabetes. 2002 Aug;110(5):235-44. PubMed PMID: 12148088. 19: Ashby J, Lefevre PA, Deghenghi R, Wallis N. Replacement of surgical castration by GnRH-inhibition or Leydig cell ablation in the male rat Hershberger antiandrogen assay. Regul Toxicol Pharmacol. 2001 Oct;34(2):188-203. PubMed PMID: 11603962. 20: Braun K, Kuhl P, Bernd M, Kutscher B. Stability of several LHRH antagonists against proteolytic enzymes and identification of degradation products by mass spectrometry. Pharmazie. 2001 Jan;56(1):45-9. PubMed PMID: 11210667.